Crinetics Pharmaceuticals (CRNX) News Today $44.43 +1.93 (+4.54%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$44.08 -0.35 (-0.79%) As of 10/8/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRNX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX)October 8 at 2:55 AM | finance.yahoo.comA Look at Crinetics Pharmaceuticals's Valuation Following FDA Approval of PALSONIFY for AcromegalyOctober 7 at 11:25 AM | finance.yahoo.comCrinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025October 6 at 4:19 PM | globenewswire.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 5, 2025 | marketbeat.comDana Pizzuti Sells 5,000 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) StockOctober 4, 2025 | insidertrades.comInsider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Sells 5,000 Shares of StockOctober 3, 2025 | marketbeat.comOppenheimer Forecasts Strong Price Appreciation for Crinetics Pharmaceuticals (NASDAQ:CRNX) StockOctober 2, 2025 | americanbankingnews.comOppenheimer Maintains Crinetics Pharmaceuticals (CRNX) Outperform RecommendationOctober 1, 2025 | msn.comCrinetics Pharmaceuticals (CRNX) Price Target Increased by 11.63% to 81.09October 1, 2025 | msn.comCrinetics Pharmaceuticals (NASDAQ:CRNX) CEO Richard Scott Struthers Sells 4,000 SharesOctober 1, 2025 | insidertrades.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Expected to Rise, Leerink Partners Analyst SaysOctober 1, 2025 | americanbankingnews.comCrinetics Pharmaceuticals (NASDAQ:CRNX) CEO Richard Scott Struthers Sells 4,000 SharesSeptember 30, 2025 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Director Matthew Fust Sells 16,000 SharesSeptember 30, 2025 | marketbeat.comJMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-ApprovalSeptember 30, 2025 | insidermonkey.comJMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-ApprovalSeptember 30, 2025 | finance.yahoo.comCrinetics Pharmaceuticals Rings the Opening BellSeptember 30, 2025 | nasdaq.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $87.00 at OppenheimerSeptember 30, 2025 | marketbeat.comMorgan Stanley Maintains Crinetics Pharmaceuticals (CRNX) Overweight RecommendationSeptember 30, 2025 | msn.comJPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight RatingSeptember 30, 2025 | finance.yahoo.comLeerink Partners Maintains Crinetics Pharmaceuticals (CRNX) Outperform RecommendationSeptember 29, 2025 | msn.comCrinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly DrugSeptember 29, 2025 | msn.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.1% - Should You Sell?September 29, 2025 | marketbeat.comMorgan Stanley Increases Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $77.00September 29, 2025 | marketbeat.comLeerink Partners Boosts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $88.00September 29, 2025 | marketbeat.comIs Crinetics Pharmaceuticals Stock a Buy?September 28, 2025 | fool.comRobert W. Baird Forecasts Strong Price Appreciation for Crinetics Pharmaceuticals (NASDAQ:CRNX) StockSeptember 28, 2025 | americanbankingnews.comJMP Securities Forecasts Strong Price Appreciation for Crinetics Pharmaceuticals (NASDAQ:CRNX) StockSeptember 28, 2025 | americanbankingnews.comCrinetics Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:CRNX)September 28, 2025 | americanbankingnews.comGoldman Sachs Maintains Crinetics Pharmaceuticals (CRNX) Neutral RecommendationSeptember 27, 2025 | msn.comCrinetics Pharma Surges After FDA OKs Its Treatment For A Form Of GigantismSeptember 26, 2025 | msn.comJMP Securities Maintains Crinetics Pharmaceuticals (CRNX) Market Outperform RecommendationSeptember 26, 2025 | msn.comCrinetics: FDA Approval And Expansion Of Palsonify In Focus, Maintaining 'Buy' RatingSeptember 26, 2025 | seekingalpha.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $40.00 at The Goldman Sachs GroupSeptember 26, 2025 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up Following Analyst UpgradeSeptember 26, 2025 | marketbeat.comCrinetics Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:CRNX)September 26, 2025 | marketbeat.comCrinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On FridaySeptember 26, 2025 | benzinga.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $143.00September 26, 2025 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $62.00 at Robert W. BairdSeptember 26, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. - Special CallSeptember 26, 2025 | seekingalpha.comCrinetics Pharmaceuticals, Inc. (CRNX) Discusses On PALSONIFY FDA Approval Call TranscriptSeptember 26, 2025 | seekingalpha.comCrinetics Pharmaceuticals trading halted, news pendingSeptember 25, 2025 | msn.comCrinetics announces FDA approval of PALSONIFYSeptember 25, 2025 | msn.comCrinetics Pharmaceuticals, Inc. (CRNX) Special Call - SlideshowSeptember 25, 2025 | seekingalpha.comCrinetics Pharmaceuticals, Inc.: Crinetics Announces FDA Approval of PALSONIFY (paltusotine) for the Treatment of Adults with AcromegalySeptember 25, 2025 | finanznachrichten.deUS FDA approves Crinetics' oral pill for rare hormone disorderSeptember 25, 2025 | msn.comCrinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with AcromegalySeptember 25, 2025 | globenewswire.comJPMorgan Chase & Co. Cuts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $52.00September 24, 2025 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.7% - What's Next?September 20, 2025 | marketbeat.comThose who invested in Crinetics Pharmaceuticals (NASDAQ:CRNX) five years ago are up 151%September 18, 2025 | finance.yahoo.comVoya Investment Management LLC Lowers Stake in Crinetics Pharmaceuticals, Inc. $CRNXSeptember 17, 2025 | marketbeat.com Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRNX Media Mentions By Week CRNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼0.590.63▲Average Medical News Sentiment CRNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼87▲CRNX Articles Average Week Get the Latest News and Ratings for CRNX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Crinetics Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Ascendis Pharma A/S News Today Viatris News Today Dr. Reddy's Laboratories News Today Moderna News Today Roivant Sciences News Today QIAGEN News Today Elanco Animal Health News Today BridgeBio Pharma News Today Verona Pharma PLC American Depositary Share News Today Revolution Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
